Characterisation of two rat mammary tumour models for breast cancer research by gene expression profiling.
Breast cancer is the most frequently occurring cancer in women. Treatment options are still an active area of research. Models used for this purpose include induced models in rodents. By the advent of microarrays it has become possible to evaluate models not only for similar morphology or selected markers by polymerase chain reaction (PCR) or immunohistochemistry but also for the expression of thousands of genes at once. This study presents gene expression profiles of the hormone-sensitive 7,12-dimethylbenzanthracene-induced and the metastasising MTLn3-model. The models are discussed for their relevance to breast cancer in humans.
Marxfeld
Heike
H
Preclinical Safety, Novartis Pharma AG, Basel, Switzerland. heike.marxfeld@eur.crl.com
Staedtler
Frank
F
Harleman
Johannes H
JH
D015127:9,10-Dimethyl-1,2-benzanthracene; D000230:Adenocarcinoma / Q000235:genetics; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D020869:Gene Expression Profiling; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics*; D020782:Matrix Metalloproteinases / Q000235:genetics; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics; D053495:Osteopontin / Q000235:genetics; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley
D053495:Osteopontin; D015127:9,10-Dimethyl-1,2-benzanthracene; D020782:Matrix Metalloproteinases